Pediatric Cardiomyopathies from the Landscape of Inherited Metabolic Disorders in Southeastern Turkey


Creative Commons License

Demir F., Topal E., Bulut F. D., Erdem S., Kor D., Atmış A., ...Daha Fazla

IRANIAN JOURNAL OF PEDIATRICS, cilt.34, sa.1, ss.141783, 2024 (SCI-Expanded)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 1
  • Basım Tarihi: 2024
  • Doi Numarası: 10.5812/ijp-141783
  • Dergi Adı: IRANIAN JOURNAL OF PEDIATRICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, Veterinary Science Database
  • Sayfa Sayıları: ss.141783
  • Çukurova Üniversitesi Adresli: Evet

Özet

Background: Cardiomyopathy (CM) is an important factor affecting inherited metabolic disorders (IMDs). Therefore, documentation of real-world data can increase awareness, and early diagnosis and treatment may improve the outcome. Objectives: The aim of this study was to delineate the underlying etiologies and clinical findings of patients with CM due to IMDs. Methods: In this single-center retrospective study, we aimed to examine the demographic, clinical, and echocardiographic data and prognosis of patients aged 0 - 18 who were diagnosed with CM associated with IMDs between 2010 and 2020. Results: A total of 102 patients were included in the study. Families with consanguineous parents constituted 84.3% of the study population. The mean age of the patients at the time of diagnosis of CM was 26.2 ± 28.2 months. Eighty-six (84.3%) of the patients were diagnosed with hypertrophic CM (HCM), 12 (11.7%) with dilated CM (DCM), and 4 (3.9%) with mixt-type CM. Of the patients, 60 (58.8%) had glycogen storage disease (GSD), 17 (16.6%) had lysosomal storage disorders (LSDs), 11 (10.7%) had fatty acid oxidation disorders, 11 (10.7%) had mitochondrial disorders, and 3 (2.9%) had amino acid and organic acid metabolism disorders. Arrhythmia was detected in 24 patients (23.5%). Fifty-six patients received enzyme replacement therapy (ERT). The echocardiographic parameters of the Pompe patients improved significantly with ERT. The mean follow-up period was 60.9 ± 54.6 months. Thirty-eight (36.1%) of 95 patients with regular follow-up died. Cardiomyopathy type did not affect mortality. Conclusions: Increasingly, cardiac complications have been defined as IMDs. Evaluation should be made in terms of IMDs in unexplained CM and rhythm disorders. On the other hand, patients with certain IMDs should be regularly screened for cardiac complications.